[PR Newswire] – NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ — Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2014 of $0.70 per share on the company’s common stock. The dividend is payable on September 9, 2014 to shareholders of record at the close of business on August 26, 2014. Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Read more on this.
Johnson & Johnson (JNJ), valued at $286.22B, opened at $101.36.
Looking at the equity, the company’s one day range is $101.02 to $101.58 with a trailing 52-week range being $85.50 to $106.74.
Johnson & Johnson (JNJ) shares are currently priced at 16.95x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -5.67x earnings multiple for the same period.
And for those looking to make a return holding the stock, the company pays shareholders $2.80 per share annually in dividends, yielding 2.70%.
Consensus earnings for the current quarter by the 16 sell-side analysts covering the stock is an estimate of $1.43 per share, which would be $0.07 better than the year-ago quarter and a $0.03 sequential decrease. The full-year EPS estimate is $5.92, which would be a $0.40 better than last year.
The quarterly earnings estimate is predicated on a consensus revenue forecast of $18.35 Billion. If reported, that would be a 4.38% increase over the year-ago quarter.
Recently, Barclays downgraded JNJ from Overweight to Equal Weight (Jan 10, 2014). Previously, RBC Capital Mkts upgraded JNJ from Sector Perform to Outperform.
When considering if perhaps the stock is under or overvalued, the average price target is $108.25, which is 6.80% above where the stock opened this morning.
Summary (NYSE:JNJ) : Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and womens health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSONS, AVEENO, CLEAN & CLEAR, DABAO, JOHNSONS Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .